Trials / Unknown
UnknownNCT03646396
Effect of Sofosbuvir-daclatasuvir on Angiogenesis
Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection
Detailed description
The study primary aim was at evaluation of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir-daclatasvir | Sofosbuvir-daclatasvir for 3 months |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2025-08-01
- Completion
- 2025-12-01
- First posted
- 2018-08-24
- Last updated
- 2018-08-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03646396. Inclusion in this directory is not an endorsement.